Home  •  Latest News  •  Submit Your News  •  Submit Your Site  •  Submit Your Event  •  Member Login     

Tuesday, September 26, 2017
 
LocalNews Homepage
 
News
• Latest News
• Subscribe to News Feed
 
Create a Press Release
• Submit Your News
 
Events
• Local Event Calendar
• Submit Your Event
 
Websites
• Search Local Websites
• Submit Your Website
 
Help
• About LocalNews
• Why Submit?
• FAQs
• Contact Us
• TOS & Privacy
 
 
Dengue Vaccine Market to Grow at a CAGR of 17.5% by 2027
 
Release Date: 4/20/2017
 

Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need


The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takeda&rsquos TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.


The global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017&ndash2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.


Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1763


 
Contact Information
E-Mail For More Information

 
Print Dengue Vaccine Market to Grow at a CAGR of 17.5% by 2027  Print this Article
 
<< Back to Latest News

 
© 2017 localnews.biz.    All Rights Reserved.